LLY vs. ZVRA
LLY (Eli Lilly and Company) and ZVRA (Zevra Therapeutics Inc.) are both stocks. Both are in the Healthcare sector — LLY in Drug Manufacturers - General, ZVRA in Biotechnology. Over the past 10 years, LLY returned 32.12%/yr vs -17.62%/yr for ZVRA. Their 0.12 correlation means their historical movements had little consistent relationship.
Performance
LLY vs. ZVRA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LLY achieves a 7.26% return, which is significantly higher than ZVRA's 6.14% return. Over the past 10 years, LLY has outperformed ZVRA with an annualized return of 32.12%, while ZVRA has yielded a comparatively lower -17.62% annualized return.
LLY
- 1D
- -0.53%
- 1M
- -3.60%
- 6M
- 11.14%
- YTD
- 7.26%
- 1Y
- 56.33%
- 3Y*
- 37.33%
- 5Y*
- 37.67%
- 10Y*
- 32.12%
- ALL TIME*
- 16.04%
ZVRA
- 1D
- -1.35%
- 1M
- -31.14%
- 6M
- 5.67%
- YTD
- 6.14%
- 1Y
- -14.40%
- 3Y*
- 24.74%
- 5Y*
- -1.18%
- 10Y*
- -17.62%
- ALL TIME*
- -23.23%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $2.62B | $2.84B | $3.35B | |
| $18.33M | $18.68M | $21.76M |
LLY vs. ZVRA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 7.26% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
ZVRA Zevra Therapeutics Inc. | 6.14% | 7.43% | 27.33% | 42.70% | -47.30% | -22.23% | 84.70% | -78.71% | -56.05% | 37.29% |
Correlation
The correlation between LLY and ZVRA is 0.17, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.17 |
Correlation (3Y) Balances recent behavior with more history. | 0.18 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.16 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.11 |
Correlation (All Time) Calculated using the full available price history since Apr 16, 2015 | 0.12 |
Fundamentals
LLY:
$1.08T
ZVRA:
$562.18M
LLY:
$28.16
ZVRA:
$2.15
LLY:
40.80
ZVRA:
4.43
LLY:
14.27
ZVRA:
4.50
LLY:
32.99
ZVRA:
2.78
LLY:
$72.25B
ZVRA:
$122.29M
LLY:
$59.75B
ZVRA:
$104.94M
LLY:
$32.97B
ZVRA:
$149.15M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LLY vs. ZVRA — Risk / Return Rank
LLY
ZVRA
LLY vs. ZVRA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Zevra Therapeutics Inc. (ZVRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LLY | ZVRA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.70 | ||
| Sortino ratioReturn per unit of downside risk | +1.97 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.02 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | 2.44 | -0.36 | +2.80 |
| Martin ratioReturn relative to average drawdown | 6.60 | -0.65 | +7.25 |
Loading charts...
Drawdowns
LLY vs. ZVRA - Drawdown Comparison
The maximum LLY drawdown since its inception was -68.24%, smaller than the maximum ZVRA drawdown of -99.27%. Use the drawdown chart below to compare losses from any high point for LLY and ZVRA.
Loading charts...
Drawdown Indicators
| LLY | ZVRA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.24% | -99.27% | +31.03% |
Max Drawdown (1Y)Largest decline over 1 year | -23.18% | -40.40% | +17.22% |
Max Drawdown (3Y)Largest decline over 3 years | -34.48% | -43.47% | +8.99% |
Max Drawdown (5Y)Largest decline over 5 years | -34.48% | -60.97% | +26.49% |
Max Drawdown (10Y)Largest decline over 10 years | -34.48% | -97.85% | +63.37% |
Current DrawdownCurrent decline from peak | -7.02% | -97.48% | +90.46% |
Average DrawdownAverage peak-to-trough decline | -19.17% | -86.53% | +67.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.56% | 22.22% | -13.66% |
Volatility
LLY vs. ZVRA - Volatility Comparison
The current volatility for Eli Lilly and Company (LLY) is 8.88%, while Zevra Therapeutics Inc. (ZVRA) has a volatility of 29.44%. This indicates that LLY experiences smaller price fluctuations and is considered to be less risky than ZVRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LLY | ZVRA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.88% | 29.44% | -20.56% |
Volatility (6M)Calculated over the trailing 6-month period | 27.69% | 49.17% | -21.48% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.37% | 65.35% | -26.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.64% | 61.11% | -28.47% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 30.37% | 81.05% | -50.68% |
Dividends
LLY vs. ZVRA - Dividend Comparison
LLY's dividend yield for the trailing twelve months is around 0.56%, while ZVRA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 0.56% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
ZVRA Zevra Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
LLY vs. ZVRA - Financials Comparison
This section allows you to compare key financial metrics between Eli Lilly and Company and Zevra Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
LLY and ZVRA have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ZVRA has higher volatility (29.44%) compared to LLY (8.88%). In terms of maximum drawdown, LLY dropped -68.24% vs ZVRA's -99.27%.
LLY currently has the higher Sharpe Ratio (1.48 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LLY and ZVRA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer